BR112022003369A2 - Combinação de uma urolitina com um tratamento de imunoterapia - Google Patents
Combinação de uma urolitina com um tratamento de imunoterapiaInfo
- Publication number
- BR112022003369A2 BR112022003369A2 BR112022003369A BR112022003369A BR112022003369A2 BR 112022003369 A2 BR112022003369 A2 BR 112022003369A2 BR 112022003369 A BR112022003369 A BR 112022003369A BR 112022003369 A BR112022003369 A BR 112022003369A BR 112022003369 A2 BR112022003369 A2 BR 112022003369A2
- Authority
- BR
- Brazil
- Prior art keywords
- urolithin
- combination
- combinations
- antibody
- immunotherapy treatment
- Prior art date
Links
- 229930186301 urolithin Natural products 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
combinação de uma urolitina com um tratamento de imunoterapia. a invenção se refere a combinações de urolitinas com agentes terapêuticos, particularmente combinações de urolitinas com tratamentos de imunoterapia, tal como terapias de bloqueio de checkpoint imune, tal como antagonistas de pd-1. a invenção também se refere a composições farmacêuticas compreendendo as referidas combinações, processos de preparação das referidas composições farmacêuticas e métodos para tratar doenças com as referidas composições. em uma modalidade, a terapia de bloqueio de checkpoint imune é selecionada de um anticorpo anti-pd-1, um anticorpo anti-pd-l1, um anticorpo anti-ctla4 ou uma proteína de fusão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1912107.8A GB201912107D0 (en) | 2019-08-22 | 2019-08-22 | Combination |
PCT/EP2020/073436 WO2021032861A1 (en) | 2019-08-22 | 2020-08-20 | Combination of an urolithin with an immunotherapy treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003369A2 true BR112022003369A2 (pt) | 2022-05-17 |
Family
ID=67999966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003369A BR112022003369A2 (pt) | 2019-08-22 | 2020-08-20 | Combinação de uma urolitina com um tratamento de imunoterapia |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210346342A1 (pt) |
EP (1) | EP4017487A1 (pt) |
JP (1) | JP2022545504A (pt) |
KR (1) | KR20220051206A (pt) |
CN (1) | CN114585386A (pt) |
AU (1) | AU2020331710A1 (pt) |
BR (1) | BR112022003369A2 (pt) |
CA (1) | CA3151999A1 (pt) |
GB (1) | GB201912107D0 (pt) |
MX (1) | MX2022002235A (pt) |
WO (1) | WO2021032861A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4284781A1 (en) | 2021-01-27 | 2023-12-06 | Vandria SA | Urolithin derivatives and methods of use thereof |
CN113813255B (zh) * | 2021-10-20 | 2023-09-01 | 山东大学 | 尿石素a及其衍生物在肿瘤免疫治疗的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
WO2007127263A2 (en) | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Therapeutic uses of urolithins |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
MX354875B (es) | 2010-12-23 | 2018-03-22 | Amazentis Sa | Composiciones y métodos para mejorar la función mitocondrial y tratar enfermedades neurodegenerativas y trastornos cognitivos. |
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
BR122022015975B1 (pt) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
AR091604A1 (es) | 2012-06-27 | 2015-02-18 | Amazentis Sa | Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto |
MX2016003292A (es) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos. |
CA2972013C (en) | 2013-12-23 | 2020-04-28 | Amazentis Sa | Process-scale synthesis of urolithins |
WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
US20180256471A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Skin Treatment Methods |
CA3092106A1 (en) | 2018-02-27 | 2019-09-06 | Amazentis Sa | Process-scale synthesis of urolithin a |
WO2019236765A1 (en) * | 2018-06-05 | 2019-12-12 | Flagship Pioneering Innovations V, Inc. | Acylated catechin polyphenols and methods of their use for the treatment of cancer |
-
2019
- 2019-08-22 GB GBGB1912107.8A patent/GB201912107D0/en not_active Ceased
-
2020
- 2020-08-20 KR KR1020227008804A patent/KR20220051206A/ko active Search and Examination
- 2020-08-20 US US17/284,363 patent/US20210346342A1/en active Pending
- 2020-08-20 CN CN202080074160.4A patent/CN114585386A/zh active Pending
- 2020-08-20 EP EP20756907.0A patent/EP4017487A1/en active Pending
- 2020-08-20 WO PCT/EP2020/073436 patent/WO2021032861A1/en unknown
- 2020-08-20 MX MX2022002235A patent/MX2022002235A/es unknown
- 2020-08-20 AU AU2020331710A patent/AU2020331710A1/en active Pending
- 2020-08-20 BR BR112022003369A patent/BR112022003369A2/pt unknown
- 2020-08-20 CA CA3151999A patent/CA3151999A1/en active Pending
- 2020-08-20 JP JP2022512347A patent/JP2022545504A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022545504A (ja) | 2022-10-27 |
KR20220051206A (ko) | 2022-04-26 |
CN114585386A (zh) | 2022-06-03 |
EP4017487A1 (en) | 2022-06-29 |
US20210346342A1 (en) | 2021-11-11 |
MX2022002235A (es) | 2022-05-24 |
GB201912107D0 (en) | 2019-10-09 |
CA3151999A1 (en) | 2021-02-25 |
AU2020331710A1 (en) | 2022-03-24 |
WO2021032861A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
MX2018007089A (es) | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
BR112016026559A8 (pt) | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
PH12018500098A1 (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
BR112022003369A2 (pt) | Combinação de uma urolitina com um tratamento de imunoterapia | |
MX2021011110A (es) | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. | |
TN2019000188A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
BR112018074152A8 (pt) | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
BR112018015826A2 (pt) | anticorpos monoclonais específicos egfl6 e métodos de seu uso | |
CO2019003865A2 (es) | Proteína terapéutica | |
BR112016023011A2 (pt) | tratamento de câncer gástrico | |
MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
SG10201811109PA (en) | Methods of treating ttp with immunoglobulin single variable domains and uses thereof | |
EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
BR112019001130A2 (pt) | uso de lactama e composição farmacêutica | |
MX2021005266A (es) | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. |